Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis
International Journal of Urology · 2026-11 · 33 (11)
DOI: 10.1111/iju.70699 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Urology, online erschienen am 03.11.2026. Verfasst von Makito Miyake. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Kashihara, Nara, Japan. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
ORCID-Profile: Makito Miyake
Zitieren
APA
Miyake, M. (2026). Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology, 33(11). https://doi.org/10.1111/iju.70699
Vancouver
Miyake M. Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology. 2026;33(11). doi:10.1111/iju.70699
BibTeX
@article{Miyake2026,
author = {Miyake, Makito},
title = {Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/iju.70699}
}
EUVIMED